Education
About Us
Working with TipRanks
Follow Us
Sera Prognostics, Inc. (SERA)
:SERA
SERA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.77 - $12.36
Previous CloseN/A
Volume57.63K
Average Volume (3M)101.67K
Market Cap
$148.02M
Enterprise Value$230.87M
Total Cash (Recent Filing)-$21.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 07, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding36,695,805
10 Day Avg. Volume92,554
30 Day Avg. Volume101,669
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1853.83
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.40K
Enterprise Value/Ebitda-7.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Sera Prognostics News
PremiumCompany Announcements
Sera Prognostics Earnings Call: Balancing Success and Challenges
PremiumCompany Announcements
Sera Prognostics Reports 2024 Financial Results and Strategic Plans
PremiumCompany Announcements
Sera Prognostics Announces $50 Million Public Offering
---
Bulls Say, Bears Say
Bulls Say
Clinical DataSERA's commercialization plans for its PreTRM test are focused on addressing a high unmet need, with impactful clinical data supporting its potential.
Market OpportunityThe market cap of $150M is considered attractive for investors with a longer-term perspective, given the >$2B US total addressable market and a differentiated test.
Bears Say
Revenue ForecastRevenue for 2024 is trimmed to $120K on low PreTRM take up ahead of reimbursement.
Revenue PerformanceThe financial results were uneventful with revenue of $29K versus the expected $75K.
---
Ownership Overview
7.97% Insiders
6.94% Mutual Funds
30.91% Other Institutional Investors
47.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SERA FAQ
What was Sera Prognostics, Inc.’s price range in the past 12 months?
Sera Prognostics, Inc. lowest stock price was $3.77 and its highest was $12.36 in the past 12 months.
What is Sera Prognostics, Inc.’s market cap?
Sera Prognostics, Inc.’s market cap is $148.02M.
When is Sera Prognostics, Inc.’s upcoming earnings report date?
Sera Prognostics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Sera Prognostics, Inc.’s earnings last quarter?
Sera Prognostics, Inc. released its earnings results on Mar 19, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.01.
Is Sera Prognostics, Inc. overvalued?
According to Wall Street analysts Sera Prognostics, Inc.’s price is currently Overvalued.
Does Sera Prognostics, Inc. pay dividends?
Sera Prognostics, Inc. does not currently pay dividends.
What is Sera Prognostics, Inc.’s EPS estimate?
Sera Prognostics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Sera Prognostics, Inc. have?
Sera Prognostics, Inc. has 36,695,805 shares outstanding.
What happened to Sera Prognostics, Inc.’s price movement after its last earnings report?
Sera Prognostics, Inc. reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -5.072%.
Which hedge fund is a major shareholder of Sera Prognostics, Inc.?
Currently, no hedge funds are holding shares in SERA
---
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
SERA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 11.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $359.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.63%
12-Months-Change
Fundamentals
Return on Equity
-55.78%
Trailing 12-Months
Asset Growth
-23.77%
Trailing 12-Months
Company Description
Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
---
SERA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements such as the successful PRIME study results and strong fundraising efforts, as well as plans for commercial expansion and strategic partnerships. However, these were balanced by challenges such as declining revenue and increased expenses, resulting in a neutral overall sentiment.Read More>---
SERA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SERA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-1.19%
reiterated a buy rating 9 days ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -1.19% per trade.
---